Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7986056 | 0.93 | PTGER1 (0.37) | CETPPTGER1GAALMNAGPR55 | |
| SCHEMBL7982389 | 0.92 | CETP (0.34) | CETPPTGER1GAALMNAKMT2A | |
| SCHEMBL7572801 | 0.89 | F2 (0.38) | UTS2RCETPPTGER1GAAGPR55 | |
| SCHEMBL8047891 | 0.88 | GAA (0.36) | UTS2RCETPPTGER1GAALMNA | |
| SCHEMBL7515830 | 0.88 | GAA (0.36) | UTS2RCETPPTGER1GAALMNA | |
| SCHEMBL7982400 | 0.87 | F2 (0.39) | UTS2RCETPPTGER1GPR55F2 | |
| SCHEMBL7986054 | 0.87 | PTGER1 (0.34) | CETPPTGER1GAALMNA | |
| SCHEMBL8058096 | 0.85 | CETP (0.38) | CETPPTGER1GAAGPR55KMT2A | |
| SCHEMBL7986061 | 0.84 | PTGER1 (0.35) | CETPPTGER1F2PRSS1PRSS2 | |
| SCHEMBL7209116 | 0.84 | GAA (0.38) | CETPPTGER1GAAKMT2ANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6297241-B1 | TREATMENT OF DISORDERS WHICH ARE RESPONSIVE TO THE OPENING OF THE LARGE CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS. | BRISTOL-MYERS SQUIBB COMPANY | 2001-10-02 | — | — | US | disclosed |
| US-6162817-A | Carbamate derivatives of diaryl 1,3,4-oxadiazolone | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-12-19 | — | — | US | disclosed |